short acting glp 1 agonists Gastric-emptying effects of short-acting versus longer-acting GLP-1 Receptor Agonists: Mascots &

Biessels GJ, Reagan LP

Side effects with survodutide were in line with those expected for GLP-1 RAs and were the principal cause of discontinuation 24.6% in the survodutide groups versus 3.9% with placebo

10.1016/j.jdiacomp.2015.07.013

Physicians may also hesitate to switch GLP1RAs, for the same reasons as patients, or because they incorrectly perceive that the HbA 1c and/or weightlowering efficacy are consistent across the GLP1RA class

DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors are included as options for combination therapy with metformin for patients who require dual therapy to meet glycemic goals

In June 2025, Eli Lilly reported Phase III ACHIEVE-1 Survodutide (BI 456906): Boehringer Ingelhium Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium